Menicon Bloom Day European wide launch, page-31

incorrect. I am no illusions the cash will get used.

It’s all relative to other microcaps at this level of market cap, not that they won’t need to raise again ‘ever’

show me another $15m market cap stock which is:

- fully cash backed
- $10m ARR recurring revenue already (yes correct - the revenue is recurring as existing customers need daily refils
- unique medical IP
- growing global pandemic (screen time)
- global distribution commencing through $700m annual revenue global giant
- more distribution agreement upside with potentially even larger global player (Johnson and Johnson taking up bloom night).

mate the SP ain’t all roses but I have been at this a long time and this is as good as it gets. Happy to just be a lone voice in the wilderness for months / years but this is going to go mental one day.

I was saying the same thing on AVS at 5c, and EGL at 3c just BTW.

Deep value doesn’t care about the SP short term